LLLT in the Lancet Top 20 Hit Parade

August 21, 2010 on 12:16 pm | In Uncategorized | No Comments

The paper by Roberta Chow, Mark Johnson, Rodrigo Lopes-Martins, Jan M Bjordal titled “Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials” (abstract here) reached number 17 in The Lancet top 20 most downloaded papers for 2010. The full top 20 list is here:

1. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study
|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q9B7JP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

2. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q0BGJP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qR2PJP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

3. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qI2YJP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q927SP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

4. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q02GSP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qRTGSP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

5. Biological, clinical, and ethical advances of placebo effects
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qITPSP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qI271P1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

6. Clinical assessment incorporating a personal genome
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q92G1P1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q02P1P1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

7. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qRTP1P1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qITY1P1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

8. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q9T7AP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q0TGAP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

9. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qRKPAP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qIKYAP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

10. Ticagrelor in ACS: redefining a new standard of care?
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q9K7JP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q0KGJP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

11. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qRBPJP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qIBYJP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

12. Use of procalcitonin to reduce patients’ exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q9B7SP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q0BGSP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

13. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qR2PSP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qI2YSP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

14. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qAB7JP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q1BGJP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

15. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qS2PJP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qJ2YJP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

16. Ageing populations: the challenges ahead
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qA27SP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q12GSP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

17. Efficacy of low-level laser therapy in the management of neck pain: a systematic review and meta-analysis of randomised placebo or active-treatment controlled trials
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qSTGSP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qJTPSP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

18. Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): a randomised controlled superiority trial
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qJ271P1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qA2G1P1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

19. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/q12P1P1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qSTP1P1F/uM3DI5/xJ70QP1F/cwindows%2D1252>

20. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qJTY1P1F/uM3DI5/xJ70QP1F/cwindows%2D1252>|FULL TEXT|<http://mail.elsevier-alerts.com/go.asp?/bELA001/mYS71P1F/qAT7AP1F/uM3DI5/xJ70QP1F/cwindows%2D1252>


THE LANCET ® is a registered trademark of Elsevier Properties SA, used under license.

Contact THOR

No Comments yet »

RSS feed for comments on this post. TrackBack URI

Leave a comment

XHTML: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>

Copyright © 2010 THOR Photomedicine Ltd. Entries and comments feeds.
THOR theme design by MELT.